MyMD Pharmaceuticals Enrolls First Person in Phase 2 Clinical Trial of MYMD-1 as a Treatment for Delaying Aging and Expanding Healthy Life Expectancy

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (” MyMD” or “the Firm”), a medical stage pharmaceutical company dedicated to prolonging healthy lifespan, today announced that the first client has actually been enrolled in the Firm’s Phase 2 scientific test of lead candidate MYMD-1, an oral immune regulator medicine, as a therapy for delaying aging and also increasing healthy and balanced lifespan.

The key endpoint for the Stage 2 double-blind, placebo-controlled clinical trial is to accomplish a reduction in the circulating degrees of (TNF-α), growth death variable receptor I (TNFRI) and also IL-6. TNF-α as well as IL-6 are the proteins in the body that cause inflammation and help activate the procedure of aging. The secondary procedures of the trial will certainly be the security, tolerability, as well as pharmacokinetics in this populace of individuals.

” In a Stage 1 professional test of MYMD-1, we demonstrated the drug’s statistically significant efficiency in decreasing levels of TNF-α, a principal in causing pathological aging, in the blood. The FDA has actually authorized TNF-α decrease as the primary endpoint for our Phase 2 study, which we believe placements us well for an effective Phase 2 end result,” claimed Chris Chapman, M.D., President, Supervisor and Chief Medical Police Officer of MyMD. “The initiation of person registration in this study developments our objective to slow the aging procedure, avoid loss of muscle mass tissue in aging, restriction frailty, and also prolong healthy lifespan.”

MyMD has actually mentioned that there are no FDA-approved medications for treating aging problems and also prolonging healthy lifespan humans, a market expected to be at the very least $600 billion by 20251 according to a major investment bank. TNF-α blockers are the most proposed medications by profits, a global market of roughly $40 billion each year,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would certainly boost life span by one year deserves $38 trillion and also by 10 years deserves $367 trillion.

In addition to aging, MYMD-1’s distinct activity in controling the immune system and also dealing with chronic inflammation is being established for the therapy of autoimmune condition, consisting of rheumatoid arthritis (RA), multiple sclerosis (MS), diabetes, and also inflammatory digestive tract disease.

” We plan to start composing methods for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The climbing occurrence of rheumatoid joint inflammation and also various other autoimmune and inflammatory conditions are driving demand for TNF preventions like MYMD-1, and our team believe our by mouth carried out medicine with extremely reduced toxicity would be disruptive to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid arthritis influences about 40 million people around the world.4.

Concerning MYMD-1.

Originally created for autoimmune illness, MYMD-1’s key function is to slow the aging process, avoid sarcopenia as well as frailty, and also prolong healthy lifespan. Because it can go across the blood-brain barrier and also gain access to the main nervous system (CNS), MYMD-1 is likewise positioned to be a feasible treatment for brain-related conditions. Its mechanism of activity as well as efficacy in diseases consisting of several sclerosis (MS) and thyroiditis have been examined through partnerships with several academic establishments. MYMD-1 is additionally showing pledge in pre-clinical research studies as a possible therapy for article- COVID-19 difficulties and as an anti-fibrotic and also anti-proliferation healing.

MYMD-1 has actually revealed effectiveness in pre-clinical research studies in regulating the immune system by executing as a discerning inhibitor of lump death factor-alpha (TNF-α), a vehicle driver of persistent inflammation. Unlike other treatments, MYMD-1 has been displayed in these pre-clinical studies to uniquely block TNF-α when it ends up being overactivated in autoimmune conditions and cytokine tornados, but not block it from doing its regular task of being a very first -responder to any kind of regular kind of moderate infection. MYMD-1’s ease of oral application is one more differentiator contrasted to presently available TNF-α blockers, all of which call for delivery by injection or mixture. No authorized TNF prevention has actually ever before been dosed orally. Furthermore, the drug is not immunosuppressive as well as has actually not been shown to create the significant negative effects common with conventional treatments that treat inflammation.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical firm committed to prolonging healthy life expectancy, is focused on creating 2 unique restorative systems that deal with the reasons for illness instead of just addressing the signs and symptoms. MYMD-1 is a medication system based upon a medical stage little particle that regulates the immune system to regulate TNF-α, which drives chronic swelling, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost longevity, as well as treat autoimmune conditions as well as COVID-19- associated anxiety. The Company’s second drug system, Supera-CBD, is being created to deal with chronic pain, dependency and also epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and also is being developed to deal with and improve upon the quickly growing CBD market, that includes both FDA approved medicines and CBD products not currently managed as medications. For additional information, go to www.mymd.com.